A Marfan syndrome genetic test examines FBN1, the gene that provides instructions for fibrillin-1, an essential component of connective tissue. A pathogenic FBN1 variant can support or establish a diagnosis when combined with aortic, eye, skeletal, skin, lung, and family findings. Testing is especially useful when features are incomplete, a child is too young to meet full clinical criteria, or relatives need targeted testing for a known family variant. The result is not interpreted in isolation: some FBN1 variants cause classic Marfan syndrome, while others are associated with isolated ectopia lentis, MASS phenotype, stiff skin syndrome, or other fibrillin-related presentations. A negative result does not exclude Marfan syndrome, and a variant of uncertain significance should not be treated as a confirmed diagnosis. Because the most serious risk is enlargement or dissection of the aorta, anyone with a strong clinical suspicion needs cardiovascular evaluation and surveillance even while genetic testing is pending.
- A pathogenic or likely pathogenic FBN1 variant can clarify Marfan syndrome and enable accurate testing of relatives.
- Clinical diagnosis also depends on aortic measurements, ectopia lentis, systemic features, and family history.
- A positive FBN1 result does not predict the exact severity or age of an aortic complication.
- A negative test does not eliminate Marfan syndrome or another inherited aortopathy.
- A variant of uncertain significance should not determine surgery, pregnancy restrictions, or predictive family testing by itself.
- Each child of a person with a pathogenic FBN1 variant generally has a 50% chance of inheriting it.
Table of Contents
- When FBN1 Testing Is Used
- How Genetic Results Fit the Clinical Diagnosis
- FBN1 Testing Methods and Panel Choices
- Positive, Negative, and Uncertain Results
- Aortic and Systemic Care After Testing
- Testing Children and Young Adults
- Family Risk, Pregnancy, and Reproductive Options
- Questions for Clinicians and the Laboratory
When FBN1 Testing Is Used
Marfan syndrome is a systemic connective tissue disorder with highly variable expression. Some people have obvious findings across several organ systems, while others have only aortic enlargement, lens dislocation, or skeletal features for many years. Genetic testing is most valuable when it answers a specific diagnostic or family question.
Testing may be considered in someone with aortic root dilation or dissection at a young age, ectopia lentis, a combination of characteristic skeletal and skin findings, a close relative with Marfan syndrome, or features that overlap another heritable thoracic aortic disease. It is also useful when a child has suggestive findings but has not yet developed age-dependent manifestations.
Testing does not replace urgent aortic assessment
A person with chest, back, neck, or abdominal pain suggestive of acute aortic disease needs emergency assessment, not outpatient genetic testing. Likewise, a person with suspected Marfan syndrome should have appropriate aortic imaging even if the molecular result is pending or negative. The danger comes from the current condition of the aorta, not from whether a report has been issued.
Genetic testing can refine long-term surveillance, identify relatives who need imaging, and distinguish overlapping syndromes. It cannot show the present aortic diameter or rule out an acute dissection.
Starting with the most informative relative
When several relatives have possible Marfan syndrome, testing usually begins with the person who has the clearest phenotype—such as documented aortic root aneurysm, ectopia lentis, or a clinical diagnosis. If a pathogenic variant is found, unaffected relatives can have targeted testing. This is more informative than testing a mildly affected or healthy relative first without knowing the family’s molecular cause.
If an affected relative is unavailable, a genetics team can determine whether single-gene FBN1 testing or a broader thoracic aortic aneurysm panel is more appropriate.
How Genetic Results Fit the Clinical Diagnosis
Marfan syndrome is diagnosed through a combination of clinical criteria, imaging, family history, and molecular evidence. The revised Ghent framework gives particular weight to aortic root enlargement or dissection, ectopia lentis, a pathogenic FBN1 variant known to be associated with aortic disease, and a systemic score based on other manifestations.
Aortic findings
The aortic root is measured by echocardiography and interpreted relative to body size and age, often using a Z score in children and younger people. Computed tomography or magnetic resonance imaging may be used to examine the rest of the aorta or clarify anatomy. A single measurement should be interpreted by clinicians familiar with technique, indexing, and serial change.
Aortic enlargement is central to diagnosis and management, but it is not unique to Marfan syndrome. Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, bicuspid aortic valve, familial thoracic aortic aneurysm, and other conditions can produce overlapping vascular findings.
Eye and systemic findings
Ectopia lentis, or displacement of the eye’s lens, is a major Marfan feature. A slit-lamp examination after pupil dilation is more reliable than a routine vision screen. Severe nearsightedness, retinal detachment, glaucoma, and cataract may also occur but are not individually diagnostic.
Systemic features can include long fingers, disproportionate arm span, chest wall deformity, scoliosis, flat feet, protrusio acetabuli, reduced elbow extension, characteristic facial features, spontaneous pneumothorax, skin striae not explained by weight change or pregnancy, and dural ectasia. Tall stature alone is not enough to diagnose Marfan syndrome.
The same gene can produce different phenotypes
FBN1 variants are associated with a spectrum. Some cause classic Marfan syndrome with aortic risk; others cause isolated ectopia lentis, MASS phenotype, acromicric or geleophysic dysplasia, stiff skin syndrome, or neonatal Marfan syndrome. The location and molecular mechanism of a variant can sometimes provide clues, but genotype rarely predicts the full course for one person.
This is why a report saying “pathogenic in FBN1” still needs phenotype-specific interpretation. The laboratory should explain which FBN1-related condition is supported and whether the variant has established association with aortic disease.
Differential diagnosis matters
A person with arterial tortuosity, widespread aneurysms, hypertelorism, bifid uvula, translucent skin, easy bruising, or organ rupture may need evaluation for another syndrome. A broad panel may include TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB2, TGFB3, SKI, ACTA2, MYH11, MYLK, COL3A1, and other genes. Distinguishing Loeys-Dietz syndrome or vascular Ehlers-Danlos syndrome can change arterial imaging, surgical planning, and counseling.
FBN1 Testing Methods and Panel Choices
Clinical testing generally uses DNA from blood or saliva. The laboratory sequences FBN1 coding exons and nearby splice regions and should also assess exon-level or whole-gene deletions and duplications. Some pathogenic variants are missed if a test performs sequencing without copy-number analysis.
Single-gene FBN1 testing
Single-gene testing is reasonable when the clinical picture strongly suggests Marfan syndrome, particularly with ectopia lentis and aortic root disease. It limits unrelated findings and can simplify interpretation. A laboratory may use next-generation sequencing with Sanger confirmation or another validated method.
If sequencing is negative, deletion/duplication analysis should be confirmed. Rare deep intronic or regulatory variants, complex structural changes, and mosaicism may require RNA studies, genome sequencing, or specialized analysis.
Multigene aortopathy panel
A panel is often preferable when features overlap multiple syndromes, when aortic disease is the main presentation, or when the family diagnosis is uncertain. The benefit is simultaneous assessment of several actionable causes. The drawback is a higher likelihood of uncertain findings or a result in a gene with less well-defined management.
Panel selection should be based on strong gene–disease validity rather than the largest possible gene count. The report should state which genes were analyzed, what variant types were detectable, and whether the laboratory follows disease-specific interpretation standards.
Targeted testing for a known family variant
Once a pathogenic familial variant is established, relatives should usually receive a targeted familial variant test. A true negative means the relative did not inherit that specific family variant and generally can be released from Marfan-specific surveillance attributable to it, assuming the family diagnosis is correct and there is no separate clinical indication.
Testing only a common variant or using a consumer genotyping array is not an adequate screen for Marfan syndrome. Most disease-causing FBN1 variants are rare and family-specific.
Mosaicism and sample choice
A pathogenic variant may arise after fertilization, creating mosaicism in which only a proportion of cells carry it. Low-level mosaicism can produce milder or segmental findings and may be missed in saliva or blood depending on the distribution. Testing another tissue or using a higher-sensitivity method may be considered when suspicion remains strong.
A parent can also have germline mosaicism with a negative blood test yet still have a small recurrence risk in future pregnancies. This is uncommon but relevant when a child has an apparently new variant.
Positive, Negative, and Uncertain Results
FBN1 results are usually classified as pathogenic, likely pathogenic, uncertain, likely benign, or benign. The classification reflects evidence about the variant, not the current size of the person’s aorta or the certainty of future symptoms.
Pathogenic or likely pathogenic variant
A pathogenic or likely pathogenic FBN1 variant can establish a molecular diagnosis when it fits the person’s clinical features. In some Ghent scenarios, a variant known to be associated with aortic disease contributes directly to diagnostic criteria. It also permits accurate cascade testing.
A positive result does not specify the age at which aortic enlargement will begin, the rate of growth, whether ectopia lentis will occur, or the eventual need for surgery. Even relatives with the same variant can have different severity. Care must therefore be based on serial examinations and imaging rather than presumed from genotype.
Some FBN1 variants are associated with a phenotype other than classic Marfan syndrome. The result should not be automatically converted into the label “Marfan syndrome” without considering variant mechanism and clinical findings.
Variant of uncertain significance
A variant of uncertain significance, or VUS, means the evidence is insufficient to call the change harmful or benign. It should not establish Marfan syndrome, determine preventive aortic surgery, dictate pregnancy avoidance, or be used for predictive testing of healthy relatives.
A person with a VUS may still require surveillance because of their phenotype or family history. Conversely, an unaffected person should not undergo lifelong Marfan management solely because of a VUS. Segregation testing, RNA analysis, functional data, population evidence, and future case reports may lead to reclassification.
FBN1 interpretation benefits from gene-specific expert criteria. Certain cysteine changes, splice variants, loss-of-function variants, and variants in established functional domains may carry different evidence weights. A rare missense variant is not automatically pathogenic.
Negative result
A negative result means no reportable FBN1 variant was found with the method used. It does not exclude a clinical diagnosis. The cause may be a variant not detected by the assay, mosaicism, another aortopathy gene, or a condition that is not currently genetically explained.
If the person meets clinical criteria or has aortic disease, surveillance continues regardless of the negative report. A broader panel, deletion analysis, RNA testing, genome sequencing, or periodic reanalysis may be appropriate.
A negative targeted result is different: when the exact pathogenic family variant is known and reliably excluded, it is usually a true negative for that familial condition. The distinction between a negative broad test and a true negative should be explicit.
Incidental or secondary findings
A broad genomic test may identify an actionable variant unrelated to the original Marfan question. Consent should address whether secondary findings will be reported. The presence of an unrelated variant does not explain the connective tissue phenotype unless there is a validated clinical match.
Aortic and Systemic Care After Testing
The purpose of diagnosis is to prevent complications through surveillance and timely treatment. Care is usually coordinated by cardiology, medical genetics, ophthalmology, orthopedics, and other specialists as needed.
Aortic imaging and medication
Echocardiography is used to follow the aortic root and heart valves. Cross-sectional imaging can evaluate the entire thoracic and abdominal aorta. Frequency depends on age, aortic size, growth rate, family history, pregnancy plans, and prior surgery. A stable young person and someone with rapidly enlarging aorta require different schedules.
Beta blockers or angiotensin receptor blockers may be prescribed to reduce hemodynamic stress and slow aortic enlargement. Medication choice, dose, blood pressure targets, and pregnancy safety require individualized medical supervision. Genetic testing does not replace these clinical decisions.
Preventive aortic surgery
Elective aortic root surgery can prevent dissection when performed before risk becomes unacceptable. Decisions incorporate absolute diameter, indexed measurements, rate of enlargement, family history of dissection at smaller sizes, pregnancy plans, valve anatomy, body size, and surgical expertise. Guidelines provide thresholds, but they are not a one-number rule for every person.
A VUS should never be the sole reason for surgery. A pathogenic FBN1 result may influence risk assessment, yet the current aortic measurements and clinical context remain decisive.
Activity and emergency symptoms
People with aortic enlargement are often advised to avoid high-intensity isometric exercise, heavy straining, and collision sports. Appropriate aerobic activity is usually encouraged within individualized limits. A cardiologist familiar with inherited aortic disease should provide specific recommendations rather than applying universal restrictions.
Sudden severe chest, back, neck, or abdominal pain; fainting; new shortness of breath; weakness on one side; or other stroke-like symptoms require emergency evaluation. A person with known aortic disease should tell emergency clinicians about the diagnosis immediately.
Eye, skeletal, lung, and skin care
Regular ophthalmologic assessment can detect ectopia lentis, refractive problems, glaucoma, cataract, and retinal complications. Sudden flashes, floaters, a curtain-like visual loss, or abrupt vision change requires urgent eye care.
Scoliosis, chest wall deformity, foot problems, joint pain, and early fatigue may require orthopedic, physical therapy, or pain evaluation. Spontaneous pneumothorax can present with sudden chest pain and breathlessness. Dural ectasia may contribute to low-back pain or neurologic symptoms. These manifestations are managed based on symptoms and anatomy, not solely on the genetic result.
Testing Children and Young Adults
Testing minors is appropriate when the result changes childhood surveillance. A child who carries a familial FBN1 pathogenic variant needs aortic and eye assessment even if they appear healthy. Unlike testing for an exclusively adult-onset disorder, early identification can guide immediate preventive care.
Age-dependent features
Young children may not yet have aortic enlargement, scoliosis, or a high systemic score. Body proportions also change with growth. A normal examination at one age does not permanently exclude manifestations. Genetic confirmation can therefore be especially helpful in a child from an affected family.
Very early severe presentations can include rapidly progressive aortic root enlargement, valve dysfunction, emphysema, joint contractures, and characteristic skeletal findings. These cases need specialized pediatric cardiology and genetics care rather than routine adult surveillance intervals.
School, sports, and psychosocial support
A diagnosis can affect sports participation, body image, school accommodations, and anxiety about the heart. Recommendations should preserve safe activity and normal development rather than defining the child entirely by risk. Families may benefit from clear letters for schools and coaches that specify permitted activity and emergency information without disclosing unnecessary details.
Adolescents should gradually participate in medical decisions, understand their medication and warning symptoms, and prepare for transfer to adult congenital or aortopathy care. Transition gaps can be dangerous because surveillance must continue throughout life.
Family Risk, Pregnancy, and Reproductive Options
Marfan syndrome is usually inherited in an autosomal dominant pattern. A person with a heterozygous pathogenic FBN1 variant has a 50% chance of passing it on in each pregnancy. The chance is the same regardless of the child’s sex, and every pregnancy is an independent event.
Approximately one quarter of affected individuals have a new variant and no affected parent. Even then, the individual can transmit the variant to children. Parental examination and targeted testing can distinguish an inherited variant from an apparently de novo event and identify relatives who may have subtle disease.
Cascade testing
First-degree relatives should be offered clinical evaluation and, when a family variant is known, targeted testing. Relatives who test positive need aortic and eye surveillance. Relatives who test true negative generally do not need Marfan-specific follow-up because of that family variant, though ordinary medical care and any separate findings still apply.
This reflects autosomal dominant inheritance, but variable expression means a mildly affected parent can have a more severely affected child and vice versa.
Pregnancy-related aortic risk
Pregnancy increases cardiovascular workload and can raise the risk of aortic enlargement or dissection during pregnancy and the postpartum period. Risk depends heavily on aortic dimensions, prior dissection or surgery, rate of growth, valve function, family history, and overall cardiovascular status.
Preconception evaluation should include updated imaging and consultation with cardiology, maternal-fetal medicine, genetics, and an experienced aortic team. Medication may need adjustment because some aortic drugs are not safe during pregnancy. Delivery planning and postpartum surveillance should be individualized; genetic status alone does not determine a universal delivery method.
A person with marked aortic enlargement or other high-risk features may be advised to consider aortic surgery before pregnancy or alternative reproductive options. These are complex decisions requiring current guideline-based counseling, not a fixed rule derived from the FBN1 result.
Prenatal diagnosis and PGT-M
Once the family variant is known, chorionic villus sampling or amniocentesis can test a pregnancy. In vitro fertilization with PGT-M can test embryos before transfer. Neither method can predict how severely an inherited FBN1 variant would affect a child.
Other options include donor gametes, adoption, or natural conception without fetal testing. Counseling should be nondirective and explain technical limitations, variable expression, maternal health considerations, and the family’s values.
Questions for Clinicians and the Laboratory
Consider asking:
- Do my findings meet current clinical criteria for Marfan syndrome?
- Has my aortic root been measured and indexed correctly, and has the entire aorta been assessed?
- Is single-gene FBN1 testing or a broader aortopathy panel more appropriate?
- Does the assay include deletion/duplication analysis and validated coverage of all coding exons?
- Is the reported variant specifically associated with aortic disease or another FBN1 phenotype?
- Is this result pathogenic, likely pathogenic, uncertain, or benign, and what evidence supports the classification?
- Should relatives have targeted testing, clinical imaging, or both?
- What is my individualized schedule for echocardiography and cross-sectional aortic imaging?
- Are medication, exercise, or surgical recommendations based on my current aortic measurements?
- What eye, skeletal, lung, and dural assessments are appropriate?
- How would pregnancy change my aortic risk and medication plan?
- Can prenatal diagnosis or PGT-M be arranged using the exact family variant?
- If the result is negative or uncertain, should the data be reanalyzed or expanded to another test?
A high-quality interpretation should end with a concrete care plan. It should state what the variant proves, what the clinical findings show now, what surveillance is needed, and which relatives can benefit from testing. Genetic information is most protective when it leads to timely aortic imaging and coordinated lifelong care.
References
- Dietz H. FBN1-Related Marfan Syndrome. GeneReviews®, updated 2022. Expert clinical review.
- Isselbacher EM, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. Circulation, 2022. Clinical practice guideline.
- Drackley A, et al. Interpretation and Classification of FBN1 Variants Associated With Marfan Syndrome: Consensus Recommendations From the ClinGen FBN1 Variant Curation Expert Panel. Genetics in Medicine, 2024. Expert consensus.
- Muiño-Mosquera L, et al. Management of Aortic Disease in Children With FBN1-Related Marfan Syndrome. European Heart Journal, 2024. Joint clinical statement.
- Klemenzdottir EO, et al. A Population-Based Survey of FBN1 Variants in Iceland Reveals Underdiagnosis of Marfan Syndrome. Genetics in Medicine, 2024. Population study.
- Salik I, Rawla P. Marfan Syndrome. StatPearls, updated 2023. Clinical review.
Disclaimer
This article is for general education and does not replace evaluation by cardiology, medical genetics, ophthalmology, or maternal-fetal medicine. Sudden severe chest, back, neck, or abdominal pain, fainting, acute shortness of breath, or stroke-like symptoms require emergency care. Aortic surveillance, medications, exercise limits, surgery, and pregnancy planning must be individualized from current imaging and specialist guidance.
